Active clinical trials for "Hematologic Diseases"

To determine the risk factors associated with inhibitor formation in hemophilia A and to study the mechanism of tolerance in the murine hemophilia A model.

To identify factors that affected the National Marrow Donor Program's (NMDP) success in retention of bone marrow volunteers.

To develop a clinical severity index that could prospectively identify sickle cell disease patients who were at high risk for a turbulent clinical course and a poor prognosis.

The Hematology Service provides hematology consultations for patients at the Clinical Center and participates in the training of hematology fellows. Patients with a broad range of hematologic disorders must be available in order for the senior staff of the Service to maintain clinical expertise and to provide the breadth of experience necessary for the fellowship program. The purpose of this protocol is to meet these needs by allowing the Hematology Service to see patients with a spectrum of hematologic diseases not studied on existing research protocols at the NIH. These patients will be evaluated over the course of several outpatient visits and returned to the care of their referring physicians.This study was developed to evaluate and possibly treat patients with blood disorders. The Hematology Service of the National Institutes of Health is responsible for the care of patients participating in research studies. In addition the Hematology Service also provides consultation for small groups of patients with blood disorders that have not been diagnosed or that may need special testing. This study will also provide doctors at the NIH the opportunity to learn more about a wide range of blood disorders and conditions. Patients participating in this study will be evaluated over the course of several outpatient visits and will continue to be cared for by their regular physician.

This study is designed to allow the evaluation, follow-up, and medical care of patients with blood disorders not currently participating in a research study being conducted by the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) or not being screened for participation in a study. The purpose of this study is to allow investigation into the blood disorders of patients in order to teach, learn, and gather more information about diseases of the blood. In addition, this study allows researchers the opportunity to evaluate patients referred to the Hematology Branch of the NHLBI with rare or undiagnosed diseases of the blood. This may be potentially beneficial to the patient and at the same time contribute to the development of new research ideas.

This is an observational prospective cohort study to evaluate the clinical course and outcomes of COVID-19 and the underlying disease in patients with hematologic disease (malignant or non-malignant).

Create a census for the duration of the search for French patients with SK determining epidemiological and morphological parameters, determine the true frequency of clinical symptoms and identify new ones, identify complications of the disease to improve the care of patients in the hope of a better prognosis of the disease and performing a radiological study by Voxel based morphometry MRI type (N. BODDAERT, HOPITAL Necker-Enfants Malades, Paris) Perform genetic research to identify the genetic bases of SK using CGH-array (Comparative Genomic Hybridization )

We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.

A SpetiFast multiplex PCR kit has recently been placed on the market witch can evidence the DNA of 90% of micro-organisms (bacteria and fungus) implicated in sepsis. However, the clinical impact of being able to detect the DNA of these various agents is unknown. We propose to assess the benefit to patient care of the SeptiFast multiples PCR by answering three questions : 1/in patients with septic immunosuppression, does this kit evidence etiologic agents not revealed by classical methods? 2/Does the use of PCR results permit different diagnostic hypotheses to be considered? 3/Does having the SeptiFast results entail changes to the therapeutic plan?

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.